Polycystic Ovary Syndrome Drugs Market Growth
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Global <strong>Market</strong> Study on <strong>Polycystic</strong> <strong>Ovary</strong><br />
<strong>Syndrome</strong> (PCOS) Treatment: North America<br />
Likely to Emerge as the Dominant <strong>Market</strong> in 2016
P e r s i s t e n c e M a r k e t R e s e a r c h<br />
Report Media Releases<br />
Global <strong>Polycystic</strong> <strong>Ovary</strong> <strong>Syndrome</strong> (PCOS) <strong>Drugs</strong> <strong>Market</strong><br />
to Reach US$ 1,154.8 Mn by 2024; Oral Contraceptives<br />
Drug Class to Witness High Adoption<br />
According to the latest market report published by Persistence <strong>Market</strong> Research titled ‘<strong>Polycystic</strong><br />
<strong>Ovary</strong> <strong>Syndrome</strong> <strong>Drugs</strong> <strong>Market</strong>: Global Industry Analysis and Forecast, 2016–2024’, the global<br />
polycystic ovary syndrome drugs market is expected to register a CAGR of 4.6% during the<br />
forecast period 2016–2024 and is expected to expand 1.5x in terms of revenue by 2024. The<br />
report analyzes the global PCOS drugs market performance and provides information on key<br />
drivers and trends likely to impact the market during the forecast period.<br />
<strong>Growth</strong> of the global polycystic ovary syndrome drugs market is mainly driven by increasing<br />
prevalence of the disease and a growing awareness among the patient population. Increasing<br />
purchasing power among people and rising awareness of PCOS are factors expected to drive<br />
growth of the global PCOS drugs market. The need for effective management of diseases<br />
associated with PCOS such as hirsutism, obesity, and infertility is likely to boost the demand for<br />
PCOS drugs. Also, a growing popularity of combination drugs and their rising adoption among<br />
the patient population is expected to boost revenue growth of the PCOS drugs market in the<br />
coming years. A rising expenditure on research and development activities and introduction of<br />
novel drugs is further expected to boost growth of the global polycystic ovary syndrome drugs<br />
market over the forecast period. However, lack of FDA approved drugs, a low level of awareness<br />
of PCOS in underdeveloped countries, and increasing side effects associated with generics<br />
might hamper market growth during the forecast period.<br />
Browse Complete Research Study Here @<br />
http://www.persistencemarketresearch.com/market-research/polycystic-ovariansyndrome-drugs-market.asp<br />
The global market for PCOS drugs presents several growth opportunities for market players.<br />
There is a good growth potential in emerging markets and pharmaceutical drugs manufacturers<br />
are focusing on emerging economies in the Asia Pacific and Africa such as Kenya, Nigeria, etc.<br />
to target a large patient population. Also, effective reimbursement policies and reduction in the<br />
costs of drugs used for the treatment of PCOS is likely to increase the adoption of PCOS drugs<br />
Global <strong>Polycystic</strong> <strong>Ovary</strong> <strong>Syndrome</strong> (PCOS) <strong>Drugs</strong> <strong>Market</strong> 2016-2024
P e r s i s t e n c e M a r k e t R e s e a r c h<br />
across the globe. Leading market players are also investing significantly in developing new<br />
branded drugs to treat PCOS, owing to an anticipated high rise in the global patient population.<br />
The demand for branded PCOS drugs is likely to increase significantly during the forecast<br />
period.<br />
Request For Table of Content Here @ http://www.persistencemarketresearch.com/marketresearch/polycystic-ovarian-syndrome-drugs-market/toc<br />
The global PCOS drugs market is segmented based on Drug Class into Oral Contraceptives,<br />
Insulin Sensitizing Agents, Anti-Depressants, Ornithine Decarboxylase Inhibitors, Aromatase<br />
Inhibitors, and Diuretics. The contraceptive drug class segment is projected to register a CAGR<br />
of 5.4% over the forecast period. Oral contraceptives are generally the preferred first line therapy<br />
for the treatment of PCOS as they are easily available as OTC drugs. The insulin sensitizing<br />
agent segment is expected to register a CAGR of 4.8% over the forecast period. About 70% of<br />
PCOS patients are overweight and are in the category of possible candidates for type 2<br />
diabetes. As a result, insulin sensitizing agents are the widely prescribed drugs for the treatment<br />
of PCOS today. In terms of value, the oral contraceptives and insulin sensitizing agents drug<br />
class segments are collectively expected to remain the dominant and most attractive segments<br />
over the forecast period.<br />
The global PCOS drugs market is segmented based on Distribution Channel into Hospital<br />
Pharmacies, Drug Stores/OTC, E-Commerce, and Fertility Clinics. The hospital pharmacies<br />
segment is likely to lead the global PCOS drugs market in terms of revenue growth and is<br />
estimated to be valued at US$ 575.4 Mn by the end of 2024. In terms of value, the drugs<br />
stores/OTC segment is estimated to account for 27.0% share of the overall market by the end of<br />
2016.<br />
On the basis of region, the market has been segmented into North America, Latin America,<br />
Europe, Asia Pacific, and the MEA. The North America market is expected to emerge as the<br />
dominant market for polycystic ovary syndrome drugs owing to a high diagnosis rate and<br />
increasing adoption of prescription drugs. North America is estimated to dominate the PCOS<br />
drugs market with maximum value share of the overall market by the end of 2016. The presence<br />
of well-established pharmaceutical companies in North America as well as a relatively high<br />
instance of patients being diagnosed in hospitals for PCOS is a major driver for market growth.<br />
The market in the Asia Pacific region is expected to register the highest CAGR of 5.5% over the<br />
forecast period. Significant increase in healthcare services spending along with rapid economic<br />
Global <strong>Polycystic</strong> <strong>Ovary</strong> <strong>Syndrome</strong> (PCOS) <strong>Drugs</strong> <strong>Market</strong> 2016-2024
P e r s i s t e n c e M a r k e t R e s e a r c h<br />
growth and increasing awareness about health issues are some of the key factors likely to push<br />
the sales of PCOS drugs in the APAC market.<br />
Download Research Study Here @<br />
http://www.persistencemarketresearch.com/samples/3682<br />
The report also includes detailed company profiles with company-specific long-term and shortterm<br />
strategies, key offerings, and recent developments in the polycystic ovary syndrome<br />
therapeutics market. Some of the leading companies profiled in the report are Sanofi, Novartis,<br />
Teva Pharmaceutical Industries Limited, Addex Therapeutics Ltd., BIOCAD, Merck KGaA, and<br />
AstraZeneca Plc. These companies are primarily focused on enhancing their product portfolio<br />
through research and development activities and the introduction of innovative and cost-effective<br />
treatment procedures in order to gain higher market share and to strengthen their respective<br />
position in the global market.<br />
Global <strong>Polycystic</strong> <strong>Ovary</strong> <strong>Syndrome</strong> (PCOS) <strong>Drugs</strong> <strong>Market</strong> 2016-2024
P e r s i s t e n c e M a r k e t R e s e a r c h<br />
About Us:<br />
Persistence <strong>Market</strong> Research (PMR) is a third-platform research firm. Our research model is a<br />
unique collaboration of data analytics and market research methodology to help businesses<br />
achieve optimal performance.<br />
To support companies in overcoming complex business challenges, we follow a multi-disciplinary<br />
approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying<br />
real-time data collection, big data, and customer experience analytics, we deliver business<br />
intelligence for organizations of all sizes.<br />
Our offerings include pre-built reports that address every major sale, customized solutions to<br />
cater to client-specific needs, and consulting services to offer more value addition. Our nextgeneration<br />
research approach for exploring emerging technologies has allowed us to solve the<br />
most complex problems of clients. We do not follow a reactive approach, but a pro-active one.<br />
Expert analysts at PMR keep a tab on next-generation technologies in their R&D phase and<br />
provide the latest insights into these technologies when they are being commercialized. Our<br />
ground-breaking approach allows us to deliver market solutions before the technologies reach<br />
the market.<br />
Our client success stories feature a range of clients from Fortune 500 companies to fast-growing<br />
startups. PMR’s collaborative environment is committed to building industry-specific solutions by<br />
transforming data from multiple streams into a strategic asset.<br />
Contact Us:<br />
Persistence <strong>Market</strong> Research<br />
90 Sate Street, Suite 700 Albany, NY 12207<br />
Tel: +1-518-618-1030<br />
Email: sales@persistencemarketresearch.com<br />
Website: http://www.persistencemarketresearch.com/<br />
media@persistencemarketresearch.com<br />
Stay updated with our official Blog: http://pmrblog.com<br />
Global <strong>Polycystic</strong> <strong>Ovary</strong> <strong>Syndrome</strong> (PCOS) <strong>Drugs</strong> <strong>Market</strong> 2016-2024
Change language